Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.

Allergy·2026
Same author

The prevalence of patients suffering from chronic spontaneous urticaria, in whom omalizumab cannot be stopped even after six years.

Frontiers in allergy·2024
Same author

The Chronic Angioedema Registry (CARE): Rationale, Methods and Implementation.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2024
Same author

Von Willebrand factor: a possible biomarker for disease activity in vasculitis.

Scandinavian journal of rheumatology·2024
Same author

Arerugi = [Allergy]·2023
Same author

Arerugi = [Allergy]·2023

Related Experiment Video

Updated: Jul 7, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Rituximab: beyond simple B cell depletion.

A Kessel1, I Rosner, E Toubi

  • 1Division of Clinical Immunology and Allergy, Bnai Zion Medical Center, Technion, Rappaport Faculty of Medicine, Haifa, P.O.B. 4940, Israel.

Clinical Reviews in Allergy & Immunology
|February 2, 2008
PubMed
Summary
This summary is machine-generated.

Rituximab depletes B cells to treat lymphomas and autoimmune diseases like RA and SLE. Its clinical benefits in autoimmune conditions are linked to B-cell depletion, with ongoing research into additional immune modulation mechanisms.

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Experiment Videos

Last Updated: Jul 7, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Area of Science:

  • Immunology
  • Rheumatology
  • Oncology

Background:

  • Rituximab, an anti-CD20 monoclonal antibody, is established for lymphoma treatment.
  • B cells play a role in autoimmune disease pathogenesis through autoantibody production.
  • B-cell depletion therapy shows promise in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

Purpose of the Study:

  • To review the efficacy and mechanisms of rituximab in autoimmune diseases.
  • To explore how B-cell depletion impacts clinical outcomes in autoimmune conditions.
  • To investigate alternative pathways of rituximab's therapeutic action beyond B-cell depletion.

Main Methods:

  • Review of existing clinical trial data on rituximab in autoimmune diseases.
  • Analysis of the correlation between B-cell depletion extent and clinical benefit.
  • Examination of rituximab's effects on various immune cell functions.

Main Results:

  • Clinical benefits of rituximab generally correlate with B-cell depletion duration and extent.
  • Autoantibody reduction is observed but not always consistent with clinical improvement.
  • Rituximab may influence T-cell modulation, regulatory T-cell behavior, and innate immune cell activity.

Conclusions:

  • Rituximab is effective in treating certain autoimmune diseases by depleting B cells.
  • Beyond B-cell depletion, rituximab may exert therapeutic effects through modulating other immune cells.
  • Further research is needed to fully elucidate rituximab's multifaceted mechanisms in autoimmune disease treatment.